Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale University ("Yale") today announced that the U.S. District Court for the District of Delaware has entered judgment in their favor in the trade secret misappropriation and breach of contract litigation against Avilar Therapeutics, Inc. ("Avilar") and RA Capital Management GP, LLC ("RA Capital"). The judgment follows the jury's July 24, 2026 verdict and formalizes a combined $4 million award to Yale and Biohaven.

Entered by the Honorable Jennifer L. Hall, United States District Judge, the judgment reflects the jury's findings that RA Capital and Avilar willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its 2019 confidentiality agreement with Yale. Consistent with the verdict, the Court entered judgment awarding a combined $4 million: $2 million to Yale for RA Capital's breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation.

Biohaven was represented by K&L Gates LLP and Morris James LLP. Susman Godfrey LLP and Farnan LLP represented Yale.